Efficacy and Safety Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 116 participants.
Also called NCT01327014
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 116 participants
- Sponsor
- Beijing Peking University WBL Biotech Co., Ltd.
- Registry
-
NCT01327014
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, China
- Registry status
- Completed
Technical summary
Registry record NCT01327014. Randomized; quadruple masking; primary purpose treatment. Start 2011-04 (registry gives no type); primary completion 2012-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia
- Condition
- Hyperlipidemia
- Intervention (Drug)
- XueZhiKang (XZK), a botanic product with multiple components
- Intervention (Drug)
- Placebo
- Lead sponsor
- Beijing Peking University WBL Biotech Co., Ltd.
Record details
- Record id
cardio:ct-nct01327014- Content hash
f3caea5a872d934c7be298d6a45b0d11eabdff941457a74f76c5ed89198e7646